Navigation Links
Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
Date:4/5/2013

SAN DIEGO, April 5, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in a Phase 1 clinical trial of APD334, a novel oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor for the potential treatment of autoimmune diseases.

This randomized, double-blind and placebo-controlled Phase 1 trial will evaluate the safety, tolerability and pharmacokinetics of single-ascending doses of APD334 in up to 64 healthy adult volunteers.

"We are pleased to expand our clinical-stage pipeline by initiating a Phase 1 trial of APD334, and look forward to advancing this novel compound through our validated development platform," said William R. Shanahan , M.D., Arena's Senior Vice President and Chief Medical Officer. "APD334's selectivity for the S1P1 receptor has the potential to improve upon the adverse event profile of currently available treatments for a spectrum of autoimmune diseases."

About Autoimmune DiseasesAutoimmune diseases are characterized by an inappropriate immune response against substances and tissues that are normally present in the body. In an autoimmune reaction, a person's antibodies and immune cells target healthy tissues, triggering an inflammatory response. Reducing the immune and/or inflammatory response is an important goal in the treatment of autoimmune disease.

About APD334APD334 is an orally available drug candidate discovered by Arena that targets the S1P1 receptor for the potential treatment of a number of conditions related to autoimmune diseases, including multiple sclerosis, psoriasis and rheumatoid arthritis. S1P1 receptors have been demonstrated to be involved in the modulation of several biological responses, including lymphocyte trafficking from lym
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
2. Arena Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
3. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Monday, March 4
4. Proposed Regulatory Uniformity to Boost Venture Capital Investments in Healthcare Arena, Says Frost & Sullivan
5. Arena Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference
6. Arena Pharmaceuticals and Ildong Pharmaceutical Enter Into Co-Development and License Agreement for Temanogrel, a Novel Agent for Thrombotic Diseases
7. Arena Pharmaceuticals to Webcast Live Presentation at the Piper Jaffray 24th Annual Healthcare Conference
8. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2012 Financial Results
10. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Tuesday, November 6
11. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the ... sponsored by Mission Pharmacal Company. The survey, conducted by ... support community, revealed that 74 percent of osteoporosis patients ... form other than a pill or a tablet. ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Feb. 24, 2011 GlaxoSmithKline (GSK), one of ... 2010 Environmental Stewardship Award from Nalco Company (NYSE: ... ongoing efforts to reduce its climate change impact ... http://photos.prnewswire.com/prnh/20101231/NALCOLOGO ) The Environmental Stewardship ...
... N.C., Feb. 24, 2011 Chimerix, Inc., a pharmaceutical ... announced today that Kenneth I. Moch, President and Chief ... Health Care Conference on March 1, 2011 at 3:00 ... New York City, NY. Mr. Moch will ...
Cached Medicine Technology:GlaxoSmithKline Wins Environmental Stewardship Award 2GlaxoSmithKline Wins Environmental Stewardship Award 3Chimerix to Present at the Citi 2011 Global Health Care Conference 2Chimerix to Present at the Citi 2011 Global Health Care Conference 3
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...
(Date:4/17/2014)... off depression among retirees, particularly among those who live ... The Journals of Gerontology, Series B: Psychological Sciences and ... Use and Depression Among Retired Older Adults in the ... that Internet use reduced the probability of a depressed ... , Late-life depression affects between 5 and 10 million ...
(Date:4/17/2014)... NEW YORK (17 April 2014) Population Council scientists and ... is safe, stable, and can prevent the transmission of ... and rectum in animals: HIV, herpes simplex virus 2 ... provides the first data that the gel is effective ... of efficacy in the vagina against all three viruses ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival ... cancer of the abdomen when treated with cytoreductive ... to a first-of-its-size analysis by physicians at Wake ... has the largest reported, single-center experience with cytoreductive ... Levine, M.D., and analysis of 20 years, worth ...
Breaking Medicine News(10 mins):Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... Calif., Oct. 10 AlphaDetail, Inc., a leader,in primary ... Life Sciences Industry, continues to affirm its commitment to ... on the east coast. AlphaDetail will open a ... This will benefit a large number of clients located ...
... Oct. 10 The Pennsylvania,Department of Health today ... (CDC) advisory for consumers not to eat Banquet ... due to possible,Salmonella contamination., "Federal officials have ... want to ensure Pennsylvanians are taking the,appropriate measures ...
... Inc. (OTC,Bulletin Board: SCIE) announced today that it ... Company,s quality system from the Notified,Body G-MED. SpectraScience ... II.3 of the European directive 93/42/EEC. In addition, ... Jim Hitchin the Company,s CEO said, "This certification ...
... 10 Good Shepherd,Rehabilitation Network has expanded ... The virtual store at, http://www.rehabilitystores.com with ... of secure online shopping specifically for those ... and their caregivers., "Rehability offers a ...
... Rural/Metro,Corporation announced that a majority of its ... Capital Management LLC, the Company,s,largest stockholder. During the ... and constructive dialogue. The Board,s desire is to ... remains committed,to doing what is best to enhance ...
... likely to develop breathing problems, study finds, , , WEDNESDAY, Oct. ... in their first month of life were more likely to ... a new study found. , Danish researchers found that infants ... influenzae or Moraxella catarrhalis bacteria had more ...
Cached Medicine News:Health News:AlphaDetail, Inc. Affirms Commitment to Local East Coast Presence 2Health News:Salmonella Outbreak Traced to Banquet and Store Brand Frozen Pot Pies 2Health News:SpectraScience Receives Final European Certification 2Health News:Those With Disabilities as Well as Aging Population Throughout Country Now Have Access to Thousands of Specialized Products 2Health News:Rural/Metro Board of Directors Meets With Accipiter Capital Management 2Health News:Rural/Metro Board of Directors Meets With Accipiter Capital Management 3Health News:Early Bacterial Infection May Boost Asthma Risk 2Health News:Early Bacterial Infection May Boost Asthma Risk 3
... Affinity pacemaker family offers ... truly automatic devices. Featuring ... of advanced technologies ever ... pacemaker incorporates the exclusive ...
Medtronic, Inc., a world leader in therapies for restoring people with chronic conditions to full life, introduces the AT500 Pacing System for the management of atrial tachyarrhythmias and bradycardi...
The Guidant INSIGNIA Ultra pacing system offers sophisticated patient-specific, easy-to-use features for simplified patient management and enhanced patient safety....
... Powerful, flexible, and fast, the ... combines leading edge technologies with user-oriented ... The integrated SONO MR package consists ... and control, including HI COMPOUND multi-angle ...
Medicine Products: